- Home
- ESEA vs GYRE Comparison
ESEA vs GYRE Comparison
Compare ESEA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | GYRE |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.0M | 625.6M |
| IPO Year | 2005 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ESEA | GYRE |
|---|---|---|
| Price | $64.25 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $91.75 | $18.67 |
| AVG Volume (30 Days) | 22.3K | ★ 144.2K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.94 | $27.49 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $51.00 | $4.27 |
| 52 Week High | $79.67 | $9.14 |
Technical Indicators
Market Signals| Indicator | ESEA | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 36.84 |
| Support Level | $59.55 | N/A |
| Resistance Level | $73.19 | $7.37 |
| Average True Range (ATR) | 2.24 | 0.55 |
| MACD | -0.17 | -0.18 |
| Stochastic Oscillator | 10.46 | 21.73 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.